共 9 条
- [1] Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54JOURNAL OF CROHNS & COLITIS, 2017, 11 : S304 - S305Sandborn, W. J.Rutgeerts, P.Zhang, H.Adedokun, O. J.Xu, S.Shraim, R.Marano, C.
- [2] A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-MaintenanceAMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S673 - S674Sandborn, WilliamFeagan, BrianMarano, ColleenStrauss, RichardJohanns, JewelZhang, HongyanGuzzo, CynthiaColombel, Jean-FredericReinisch, WalterGibson, PeterCollins, JudyJarnerot, GunnarRutgeerts, Paul
- [3] Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance TrialsAMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S519 - S519Sandborn, WilliamColombel, Jean-FredericFeagan, BrianMarano, ColleenStrauss, RichardHan, ChenglongGathany, TimothyJohanns, JewelZhang, HongyanGibson, PeterCollins, JudithJarnerot, GunnarRutgeerts, PaulReinisch, Walter
- [4] ACHIEVEMENT OF CLINICAL AND ENDOSCOPIC OUTCOMES BY BASELINE CORTICOSTEROID USE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RECEIVED RISANKIZUMAB INDUCTION TREATMENT: A POST-HOC ANALYSIS OF THE INSPIRE STUDYGASTROENTEROLOGY, 2024, 166 (05) : S806 - S807Bossuyt, PeterLouis, EdouardGecse, KrisztinaAbreu, Maria T.Gionchetti, PaoloRubin, David T.Marced, ElenaGonzalez, Yuri SanchezHecht, PatrickKalabic, JasminaVladea, Ramona C.Zhang, YafeiReinisch, Walter
- [5] Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER studyANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (10) : 1811 - 1818Smolen, Josef S.Kay, JonathanMatteson, Eric L.Landewe, RobertHsia, Elizabeth C.Xu, StephenZhou, YiyingDoyle, Mittie K.
- [6] Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)JOURNAL OF GASTROENTEROLOGY, 2017, 52 (10) : 1101 - 1111Hibi, ToshifumiImai, YuyaSenoo, AsakoOhta, KentaroUkyo, Yoshifumi
- [7] Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)Journal of Gastroenterology, 2017, 52 : 1101 - 1111Toshifumi HibiYuya ImaiAsako SenooKentaro OhtaYoshifumi Ukyo
- [8] Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1060 - S1060Panaccione, RemoBossuyt, PeterBlumenstein, IrinaBiedermann, LucTorres, JoanaVladea, RamonaCheng, LingZhang, YafeiKalabic, JasminaChien, KarenMorisset, PierreParkes, Gareth
- [9] ADDITIONAL RISANKIZUMAB THERAPY IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO DID NOT ACHIEVE CLINICAL RESPONSE TO INITIAL 12-WEEK INDUCTION THERAPY: AN ANALYSIS OF PHASE 3 INSPIRE AND COMMAND STUDIESGASTROENTEROLOGY, 2024, 166 (05) : S217 - S217Panaccione, RemoMelmed, GilDrobne, DavidKaur, ManreetDanese, SilvioHisamatsu, TadakazuLevine, PhillipNeimark, EzequielChen, SuCheng, LingDuan, W. RachelVladea, Ramona C.Hecht, PatrickLouis, Edouard